About Philogen

Company Description

Founded in 1996, Philogen is an Italian-Swiss biotechnology company engaged in the discovery and development of biopharmaceutical products for the treatment of life-threatening conditions.

Philogen Group mainly discovers and develops targeted anti-cancer drugs, exploiting high-affinity ligands for tumor markers. These ligands – namely human monoclonal antibodies or small molecules – are identified through Antibody Phage Display Libraries and DNA-Encoded Chemical Libraries technologies. The main therapeutic strategy of the Group for the treatment of these diseases is the so-called “tumor targeting”.

Year founded

1996

Headquarters

Piazza La Lizza 7, 53100 Siena – Italy

Shareholder information

Shares outstanding

40,611,111

IPO

Jan. 1, 2000

Stock exchange(s)

Borsa Italiana

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.